APA (7th ed.) Citation

Isa, R., Horinaka, M., Tsukamoto, T., Mizuhara, K., Fujibayashi, Y., Taminishi-Katsuragawa, Y., . . . Kuroda, J. (2022). The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. International Journal of Molecular Sciences, 23(6), 2919. https://doi.org/10.3390/ijms23062919

Chicago Style (17th ed.) Citation

Isa, Reiko, et al. "The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma." International Journal of Molecular Sciences 23, no. 6 (2022): 2919. https://doi.org/10.3390/ijms23062919.

MLA (9th ed.) Citation

Isa, Reiko, et al. "The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma." International Journal of Molecular Sciences, vol. 23, no. 6, 2022, p. 2919, https://doi.org/10.3390/ijms23062919.